JP2004505009A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505009A5
JP2004505009A5 JP2001552915A JP2001552915A JP2004505009A5 JP 2004505009 A5 JP2004505009 A5 JP 2004505009A5 JP 2001552915 A JP2001552915 A JP 2001552915A JP 2001552915 A JP2001552915 A JP 2001552915A JP 2004505009 A5 JP2004505009 A5 JP 2004505009A5
Authority
JP
Japan
Prior art keywords
agent
combination according
combination
hapten
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001552915A
Other languages
English (en)
Other versions
JP2004505009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/001737 external-priority patent/WO2001052868A1/en
Publication of JP2004505009A publication Critical patent/JP2004505009A/ja
Publication of JP2004505009A5 publication Critical patent/JP2004505009A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 以下を含む、組合せ:
a)酸化剤または還元剤;
b)タンパク質変性剤;および
c)ハプテン。
【請求項2】 請求項1に記載の組合せであって、前記酸化剤または還元剤、前記タンパク質変性剤および前記ハプテンが、単一の薬学的組成物中に処方されているか、またはそれぞれが、別個の薬学的組成物中に処方されている、組合せ。
【請求項3】 請求項1または請求項2に記載の組合せであって、前記酸化剤が、以下からなる群より選択される、組合せ:過酸化水素(H)、オゾン(O)、多原子酸素O、多原子酸素O、NaIO、ペルオキシモノ硫酸カリウム(オキソン)、D,L−S−メチルリポ酸メチルエステル、3級ブチルヒドロペルオキシド、メナジオン、ジアミド、ヨードゲン、N−ブロモスクシンイミド、オメプラゾールおよびN−エチルマレイミド。
【請求項】 請求項1〜3のうちのいずれか1項に記載の組合せであって、前記タンパク質変性剤が、以下からなる群より選択される、組合せ:アルコール、塩酸グアニジン、チオシアン酸グアニジニウム、クエン酸ナトリウム、2−メルカプトエタノール、イオン性界面活性剤サルコシル、フェノール、クロロホルムおよび尿素。
【請求項】 請求項1〜4のうちのいずれか1項に記載の組合せであって、前記ハプテンが、以下からなる群より選択される、組合せ:トリニトロフェノール(TNP)、ジニトロフェノール(DNP)、N−ヨードアセチル−N’−(5−スルホン酸1−ナフチル)エチレンジアミン(AED)、ジニトロフルオロベンゼン(DNFB)およびオバブリン(OVA)。
【請求項】 抗新生物剤をさらに含む、請求項1〜5のうちのいずれか1項に記載の組合せ。
【請求項】 前記抗新生物剤が抗脈管形成剤である、請求項に記載の組合せ。
【請求項】 請求項に記載の組合せであって、前記抗新生物剤が、以下からなる群より選択される、組合せ:アルキル化剤、代謝拮抗物質、天然産物、白金配位錯体、アントラセンジオン、置換尿素、メチルヒドラジン誘導体副腎皮質抑制剤、ホルモン、アンタゴニスト、抗癌性多糖類ならびに抗癌性草本抽出物。
【請求項】 請求項1〜8のうちのいずれか1項に記載の組合せであって、前記酸化剤がHであり、前記タンパク質変性剤がエタノールであり、そして前記ハプテンがTNPである、組合せ。
【請求項10】 請求項1〜9のうちのいずれか1項の組合せを含む、キット。
【請求項11】 以下を含む、製造物品:
a)包装材料;
b)請求項1〜9のうちのいずれか1項に記載の組合せ;および
c)該物品が新生物を処置するためのものであることを示す、標示。
JP2001552915A 2000-01-19 2001-01-18 新生物を処置するための組合せ Pending JP2004505009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17702400P 2000-01-19 2000-01-19
PCT/US2001/001737 WO2001052868A1 (en) 2000-01-19 2001-01-18 Combinations for treating neoplasms

Publications (2)

Publication Number Publication Date
JP2004505009A JP2004505009A (ja) 2004-02-19
JP2004505009A5 true JP2004505009A5 (ja) 2008-03-06

Family

ID=22646864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001552915A Pending JP2004505009A (ja) 2000-01-19 2001-01-18 新生物を処置するための組合せ

Country Status (6)

Country Link
US (1) US6811788B2 (ja)
JP (1) JP2004505009A (ja)
CN (1) CN1273146C (ja)
AU (2) AU3097701A (ja)
CA (1) CA2397598A1 (ja)
WO (1) WO2001052868A1 (ja)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US7120489B2 (en) 2000-05-08 2006-10-10 Brainsgate, Ltd. Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the BBB and cerebral blood flow
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
WO2002030473A1 (en) * 2000-10-11 2002-04-18 Targesome, Inc. Targeted therapeutic agents
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2003075860A2 (en) * 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
WO2004043218A2 (en) 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
JP2006500318A (ja) * 2002-04-25 2006-01-05 ブレインスゲート リミテッド 着臭剤の頭内神経への神経興奮性および/または神経抑制性作用を用いてbbbおよび脳循環の特性を加減する方法および装置
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
AU2003225281A1 (en) * 2002-04-30 2003-11-17 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療(a2)温熱療法と腫瘍溶解の同時治療(a3)
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
CA2516188C (en) * 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
KR20050114241A (ko) * 2003-03-19 2005-12-05 가부시키가이샤 디나벡크 겐큐쇼 골 파괴를 수반하는 염증성 질환의 치료방법
WO2004085617A2 (en) * 2003-03-21 2004-10-07 The Cleveland Clinic Foundation Timp3 as vegf inhibitor
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc COMBINED METHODS OF TREATING CANCER
DE602004026912D1 (de) * 2003-12-16 2010-06-10 Qiagen North American Holdings Formulierungen und verfahren zum denaturieren von proteinen
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
DK1720538T3 (da) * 2004-03-02 2009-01-19 Univ Arizona Fremgangsmåde til induktion af celledöd med carbonyl-scavengers
US20050266093A1 (en) * 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CA2583315A1 (en) * 2004-10-06 2006-06-01 Tiltan Pharma Ltd. Method and composition for enhancing anti-angiogenic therapy
AU2005305012C1 (en) 2004-11-05 2012-07-19 Qiagen North American Holdings, Inc. Compositions and methods for purifying nucleic acids from stabilization reagents
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2008063229A2 (en) * 2006-05-12 2008-05-29 Livingston James A Enzymatic debridement therapy for abnormal cell proliferation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CN101549153A (zh) * 2008-04-02 2009-10-07 于保法 用于自体治疗肿瘤的组合物和方法
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
DK2576638T3 (da) * 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
JP2012126649A (ja) * 2010-12-13 2012-07-05 Satoshi Anai 膀胱癌増殖抑制用組成物
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2014138338A1 (en) * 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
JP2016535014A (ja) * 2013-11-01 2016-11-10 ピットニー・ファーマシューティカルズ・ピーティーワイ・リミテッド がんの処置のための医薬の組合せ
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
BR112016026140A2 (pt) * 2014-05-09 2018-08-07 AuroMedics Pharma LLC formulações de concentrado líquido de ciclofosfamida.
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
SG11201704175WA (en) 2014-11-26 2017-06-29 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
EP3093043B1 (en) 2015-05-13 2018-11-14 Brainsgate Ltd. Implant and delivery system for neural stimulator
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2019009798A (es) 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
US10975369B2 (en) * 2017-02-27 2021-04-13 Translate Bio, Inc. Methods for purification of messenger RNA
CN107929740A (zh) * 2017-12-05 2018-04-20 上海长海医院 N‑Myc抑制剂与奥拉帕尼联用在制备治疗前列腺癌的药物中的应用
KR102014467B1 (ko) * 2017-12-14 2019-08-26 (주)녹십자웰빙 아토피성 피부염, 탈모, 상처 또는 피부 주름의 개선용 화장료 조성물 및 약학 조성물
CN109224123B (zh) * 2018-10-11 2021-04-09 成都迪康中科生物医学材料有限公司 具有抑制肿瘤作用的纳米羟基磷灰石复合材料及制备方法
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
CN109602760B (zh) * 2018-12-29 2021-03-30 江苏靶标生物医药研究所有限公司 一种铂类化合物和肝素类化合物的组合物及其应用
CN111573647A (zh) * 2020-06-16 2020-08-25 北京市创伤骨科研究所 纳米羟基磷灰石在预防或抑制骨肉瘤转移和复发中的用途
WO2022087865A1 (zh) * 2020-10-28 2022-05-05 济南嘉佐医药科技有眼公司 一种双氧水在实体肿瘤治疗中的应用
CN112691196B (zh) * 2020-12-30 2022-06-03 中山大学 一种含有金诺芬和巯基化合物的抗癌组合物及其应用
CN115969994B (zh) * 2022-10-08 2024-08-02 四川大学华西医院 一种靶向肿瘤的核壳结构纳米臭氧递送可控释放系统、制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447526A (en) 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
FR2505182A1 (fr) 1981-05-07 1982-11-12 Battentier Eric Application du coagulant (element liquide et element solide), medicament pour le traitement du cancer interne, externe et ainsi que pour le traitement de tous les squirrhes et autres champignons de ce type, naissant a l'etat verruqueux
CA1262864A (en) 1982-09-17 1989-11-14 Clarence D. Cone Method for producing oncolysis
US4804480A (en) 1986-12-29 1989-02-14 E. I. Du Pont De Nemours And Company Destruction of nitrophenols
JPH0629196B2 (ja) * 1987-12-01 1994-04-20 甲子郎 梅村 超音波による腫瘍治療用生理作用増強剤
US5156841A (en) 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5215899A (en) 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
EP0858327A2 (en) 1995-09-25 1998-08-19 Samir Chachoua Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
WO1998003195A1 (en) 1996-07-18 1998-01-29 Arch Development Corporation Methods and compositions for modulation of growth response
KR20000076115A (ko) * 1997-03-10 2000-12-26 와일러 제임스 에프. 이종 유전자의 일시적이고 선택적인 발현을 위한 산화 스트레스를 생성하는 광역학적 치료요법
JPH11171788A (ja) * 1997-12-11 1999-06-29 Toray Ind Inc C型肝細胞癌再発抑制剤
US6545139B1 (en) 1998-03-13 2003-04-08 Baylor College Of Medicine DNA sequence encoding the p99 gene and kits for the detection of neoplasia
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia

Similar Documents

Publication Publication Date Title
JP2004505009A5 (ja)
ATE407699T1 (de) Wasserlösliche zusammensetzungen enthaltend bioaktive lipohile komponenten
EP1089715B8 (en) Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IL167038A (en) Pyrazole derivatives, pharmaceutical compositions containing the same, use thereof in the manufacture of medicaments and intermediate for production thereof
PH12012501687A1 (en) Acetylcysteine composition and uses therefor
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2007124153A3 (en) Water-soluble pharmaceutical compositions of hops resins
IL191486A0 (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
JP2005532990A5 (ja)
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
NO20023875L (no) Stabilt nasalt, oralt eller sublingualt anvendbart preparat
JP2004514650A (ja) デヒドロアスコルビン酸処方物およびその使用
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
DK1399596T3 (da) Fremgangsmåde til törring af en saccharoseoplösning, det derved opnåede produkt og anvendelse heraf
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
WO2005011608A3 (en) PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
FR2838642B1 (fr) Utilisation d'une cyclodextrine en tant qu'agent nacrant et compositions nacrees
JP2005535644A5 (ja)
CN102526104B (zh) 一种复方治疗脚气药液及其制备方法
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
IL192820A (en) Dimeric derivatives of indoloquinoxaline, process for the preparation thereof, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of viral infections